TX200 (CAR-Treg cell therapy)
GPTKB entity
Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:CAR-Treg_therapy
gene therapy |
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
gptkb:Sangamo_Therapeutics
|
| gptkbp:goal |
prevent organ rejection
|
| https://www.w3.org/2000/01/rdf-schema#label |
TX200 (CAR-Treg cell therapy)
|
| gptkbp:indication |
kidney transplantation
|
| gptkbp:mechanismOfAction |
engineered regulatory T cells expressing chimeric antigen receptor
|
| gptkbp:region |
gptkb:Europe
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
gptkb:clinical_trial
|
| gptkbp:target |
gptkb:HLA-A2
|
| gptkbp:bfsParent |
gptkb:Sangamo_Therapeutics,_Inc.
|
| gptkbp:bfsLayer |
6
|